148 related articles for article (PubMed ID: 37876503)
1. Toxicity to intravitreal melphalan in a patient with retinoblastoma.
Solaz-Ruiz MG; Pérez LA; Cauto-Picazo C; Barranco-González H; Pascual-Camps I; España-Gregori E
Rom J Ophthalmol; 2023; 67(3):305-308. PubMed ID: 37876503
[No Abstract] [Full Text] [Related]
2. Ocular toxicity of intravitreal melphalan for retinoblastoma in Chinese patients.
Xue K; Ren H; Meng F; Zhang R; Qian J
BMC Ophthalmol; 2019 Feb; 19(1):61. PubMed ID: 30808420
[TBL] [Abstract][Full Text] [Related]
3. Intravitreal HDAC Inhibitor Belinostat Effectively Eradicates Vitreous Seeds Without Retinal Toxicity In Vivo in a Rabbit Retinoblastoma Model.
Kaczmarek JV; Bogan CM; Pierce JM; Tao YK; Chen SC; Liu Q; Liu X; Boyd KL; Calcutt MW; Bridges TM; Lindsley CW; Friedman DL; Richmond A; Daniels AB
Invest Ophthalmol Vis Sci; 2021 Nov; 62(14):8. PubMed ID: 34757417
[TBL] [Abstract][Full Text] [Related]
4. Intravitreal melphalan hydrochloride vs propylene glycol-free melphalan for retinoblastoma vitreous seeds: Efficacy, toxicity and stability in rabbits models and patients.
Bogan CM; Pierce JM; Doss SD; Tao YK; Chen SC; Boyd KL; Liao A; Hsieh T; Abramson DH; Francis JH; Friedman DL; Richmond A; Daniels AB
Exp Eye Res; 2021 Mar; 204():108439. PubMed ID: 33444583
[TBL] [Abstract][Full Text] [Related]
5. Addition of intravitreal carboplatin with melphalan for management of vitreous seeding in retinoblastoma.
Riazi-Esfahani H; Masoomian B; Khodabandeh A; Amini A; Taghizadeh S; Boujabadi L; Sharifkashani S; Shields CL; Ghassemi F
Graefes Arch Clin Exp Ophthalmol; 2023 Apr; 261(4):1167-1175. PubMed ID: 36401651
[TBL] [Abstract][Full Text] [Related]
6. Intravitreal melphalan for persistent or recurrent retinoblastoma vitreous seeds: preliminary results.
Shields CL; Manjandavida FP; Arepalli S; Kaliki S; Lally SE; Shields JA
JAMA Ophthalmol; 2014 Mar; 132(3):319-25. PubMed ID: 24407202
[TBL] [Abstract][Full Text] [Related]
7. Intravitreal melphalan for refractory or recurrent vitreous seeding from retinoblastoma.
Ghassemi F; Shields CL
Arch Ophthalmol; 2012 Oct; 130(10):1268-71. PubMed ID: 23044940
[TBL] [Abstract][Full Text] [Related]
8. TOXICITY AND EFFICACY OF INTRAVITREAL MELPHALAN FOR RETINOBLASTOMA: 25 µg Versus 30 µg.
Liao A; Hsieh T; Francis JH; Lavery JA; Mauguen A; Brodie SE; Abramson DH
Retina; 2021 Jan; 41(1):208-212. PubMed ID: 32106160
[TBL] [Abstract][Full Text] [Related]
9. Local and systemic toxicity of intravitreal melphalan for vitreous seeding in retinoblastoma: a preclinical and clinical study.
Francis JH; Schaiquevich P; Buitrago E; Del Sole MJ; Zapata G; Croxatto JO; Marr BP; Brodie SE; Berra A; Chantada GL; Abramson DH
Ophthalmology; 2014 Sep; 121(9):1810-7. PubMed ID: 24819859
[TBL] [Abstract][Full Text] [Related]
10. Diffuse chorioretinal atrophy after a single standard low- dose intravitreal melphalan injection in a child with retinoblastoma: a case report.
Chao A; Kao LY; Liu L; Wang NK
BMC Ophthalmol; 2016 Mar; 16():27. PubMed ID: 26975871
[TBL] [Abstract][Full Text] [Related]
11. Combined intravitreal melphalan and topotecan for refractory or recurrent vitreous seeding from retinoblastoma.
Ghassemi F; Shields CL; Ghadimi H; Khodabandeh A; Roohipoor R
JAMA Ophthalmol; 2014 Aug; 132(8):936-41. PubMed ID: 24789622
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of intravitreal topotecan dose levels, toxicity and efficacy for retinoblastoma vitreous seeds: a preclinical and clinical study.
Bogan CM; Kaczmarek JV; Pierce JM; Chen SC; Boyd KL; Calcutt MW; Bridges TM; Lindsley CW; Nadelmann JB; Liao A; Hsieh T; Abramson DH; Francis JH; Friedman DL; Richmond A; Daniels AB
Br J Ophthalmol; 2022 Feb; 106(2):288-296. PubMed ID: 33972235
[TBL] [Abstract][Full Text] [Related]
13. Intravitreal chemotherapy for vitreous disease in retinoblastoma revisited: from prohibition to conditional indications.
Munier FL; Gaillard MC; Balmer A; Soliman S; Podilsky G; Moulin AP; Beck-Popovic M
Br J Ophthalmol; 2012 Aug; 96(8):1078-83. PubMed ID: 22694968
[TBL] [Abstract][Full Text] [Related]
14. Combined intravitreal melphalan and intravenous/intra-arterial chemotherapy for retinoblastoma with vitreous seeds.
Lee JH; Han JW; Hahn SM; Lyu CJ; Kim DJ; Lee SC
Graefes Arch Clin Exp Ophthalmol; 2016 Feb; 254(2):391-4. PubMed ID: 26511530
[TBL] [Abstract][Full Text] [Related]
15. Intravitreal Lower-Dose (20 µg) Melphalan for Persistent or Recurrent Retinoblastoma Vitreous Seeds.
Tuncer S; Balcı Ö; Tanyıldız B; Kebudi R; Shields CL
Ophthalmic Surg Lasers Imaging Retina; 2015 Oct; 46(9):942-8. PubMed ID: 26469234
[TBL] [Abstract][Full Text] [Related]
16. The classification of vitreous seeds in retinoblastoma and response to intravitreal melphalan.
Francis JH; Abramson DH; Gaillard MC; Marr BP; Beck-Popovic M; Munier FL
Ophthalmology; 2015 Jun; 122(6):1173-9. PubMed ID: 25795478
[TBL] [Abstract][Full Text] [Related]
17. Intravitreal injection of melphalan in the treatment of retinoblastoma with vitreous cavity seeding.
Sun YB; Hui P; Punyara K; Bi MC; Li SH; Teng SY; Song E
Chin Med J (Engl); 2013; 126(8):1587. PubMed ID: 23595400
[No Abstract] [Full Text] [Related]
18. Not All Seeds Are Created Equal: Seed Classification Is Predictive of Outcomes in Retinoblastoma.
Berry JL; Bechtold M; Shah S; Zolfaghari E; Reid M; Jubran R; Kim JW
Ophthalmology; 2017 Dec; 124(12):1817-1825. PubMed ID: 28655537
[TBL] [Abstract][Full Text] [Related]
19. Pathological findings in enucleated eyes after intravitreal melphalan injection.
Ghassemi F; Amoli FA
Int Ophthalmol; 2014 Jun; 34(3):533-40. PubMed ID: 24043335
[TBL] [Abstract][Full Text] [Related]
20. [Short-term efficacy of intravitreal injection of melphalan for refractory vitreous seeding from retinoblastoma].
Xue K; Ren H; Zhang R; Yuan YF; Qian J
Zhonghua Yan Ke Za Zhi; 2017 Aug; 53(8):570-574. PubMed ID: 28851196
[No Abstract] [Full Text] [Related]
[Next] [New Search]